TrialEuropean journal of cancer care2018

Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study.

A A Khalafallah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.